Back to top
more

MEDIFAST (MED)

(Delayed Data from NYSE)

$19.88 USD

19.88
217,384

+0.18 (0.91%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $19.88 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 251)

Industry: Food - Miscellaneous

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Are Investors Undervaluing MEDIFAST (MED) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges

by Zacks Equity Research

Medifast's Q3 results lower earnings and revenues, highlighting challenges in customer acquisition. Management issues soft guidance for the fourth quarter.

Medifast (MED) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Medifast (MED) delivered earnings and revenue surprises of 333.33% and 3.48%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Medifast Gears Up for Q3 Earnings: Here's What You Should Know

by Zacks Equity Research

MED's Q3 results may reflect customer acquisition challenges and a decline in active earning OPTAVIA Coaches due to the increasing adoption of GLP-1 medications.

Medifast Drives Growth With Weight Loss Transformation Strategies

by Zacks Equity Research

MED is striving to excel in the evolving weight loss market where GLP-1 medication adoption is reshaping the industry dynamics amid macroeconomic challenges.

Medifast Trades Near 52-Week Low: Buy, Hold or Sell MED Stock?

by Zacks Equity Research

Amid hurdles like competition and a dynamic consumer landscape, Medifast is taking steps to realign its strategy and capitalize on emerging opportunities.

Medifast (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medifast's (MED) Strategies Aid Amid Evolving Market Demands

by Zacks Equity Research

Medifast (MED) is making efforts to thrive in the rapidly evolving weight loss market, as the adoption of GLP-1 medications reshapes industry dynamics.

Medifast (MED) Tumbles 25% in 3 Months: Should You Buy Now?

by Zacks Equity Research

Medifast (MED) is encountering difficulties in attracting customers due to a reduction in the number of active OPTAVIA Coaches and diminished productivity per Coach.

Medifast (MED) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Medifast's (MED) Q2 results highlight the challenges of poor customer acquisition. However, the company is focusing strategically on medically supported weight loss, indicating potential for growth.

Medifast (MED) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Medifast (MED) delivered earnings and revenue surprises of 155.56% and 5.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Q2 Earnings in the Cards: Factors to Watch

by Zacks Equity Research

Medifast's (MED) Q2 results are likely to reflect customer acquisition challenges stemming from the growth of GLP-1 medications in markets.

Post Holdings (POST) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Post Holdings (POST) delivered earnings and revenue surprises of 27.27% and 3.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Lags Industry in 3 Months: How to Play Ahead?

by Zacks Equity Research

While Medifast (MED) is implementing a series of measures to propel its growth trajectory, the challenges related to customer acquisition and high marketing expenses keep it in a tight spot.

Medifast (MED) Tumbles More Than 40% in 3 Months: Here's Why

by Zacks Equity Research

Medifast (MED) battles persistent customer acquisition challenges aggravated by macroeconomic factors and the rising popularity of weight loss medications.

Medifast (MED) Q1 Earnings Miss Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Medifast's (MED) first-quarter results reflect challenges related to a decline in active earning OPTAVIA Coaches, lower coach productivity and soft sales volume.

Medifast's (MED) Transformation on Track Amid Macro Headwinds

by Zacks Equity Research

Medifast (MED) adapts to shifting consumer behavior to maintain its relevance. However, it is facing difficulties in attracting customers due to the rapidly changing economy and inflation.

MEDIFAST (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

MEDIFAST (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medifast (MED) Soars 5.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Medifast (MED) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Innovations Aid Medifast (MED), Lower Customer Attraction Ails

by Zacks Equity Research

Medifast (MED) is foraying into medically supported weight management and sports nutrition segments. However, it continues to encounter difficulties in attracting customers.

Medifast (MED) Q4 Earnings Beat Estimates, Revenues Dip Y/Y

by Zacks Equity Research

Medifast's (MED) Q4 results reflect the impacts of poor customer acquisition. However, it is showing resilience, banking on its strategic focus on medically supported weight loss, indicating potential for growth.

Medifast (MED) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Medifast (MED) delivered earnings and revenue surprises of 10.10% and 9.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Q4 Earnings Coming Up: What Should You Know?

by Zacks Equity Research

Medifast's (MED) fourth-quarter results are likely to reflect the impacts of macroeconomic challenges like inflation, while key growth initiatives like innovation bode well.

Mondelez (MDLZ) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Mondelez (MDLZ) delivered earnings and revenue surprises of 7.69% and 0.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Medifast's (MED) Holistic Health Solution, Innovation Bode Well

by Zacks Equity Research

Medifast's (MED) focus on combining lifestyle coaching with innovative health solutions and targeting diverse markets bode well amid challenges in customer acquisition and high costs.